Selected article for: "describe virus and mortality morbidity"
Author: NISREEN M.A. OKBA; Marcel A Muller; Wentao Li; Chunyan Wang; Corine H. GeurtsvanKessel; Victor M. Corman; Mart M. Lamers; Reina S. Sikkema; Erwin de Bruin; Felicity D. Chandler; Yazdan Yazdanpanah; Quentin Le Hingrat; Diane Descamps; Nadhira Houhou-Fidouh; Chantal B. E. M. Reusken; Berend-Jan Bosch; Christian Drosten; Marion P.G. Koopmans; Bart L. Haagmans
Title: SARS-CoV-2 specific antibody responses in COVID-19 patients
  • Document date: 2020_3_20
    • ID: 9595vm0k_2
    Snippet: Validated serologic assays are crucial for patient contact tracing, identifying the viral reservoir hosts and for epidemiological studies. Epidemiological studies are urgently needed to help uncover the burden of disease, in particular, the rate of asymptomatic infections, and to get better estimates on morbidity and mortality. Additionally, these epidemiological studies can help reveal the extent of virus spread in households, communities and sp.....
    Document: Validated serologic assays are crucial for patient contact tracing, identifying the viral reservoir hosts and for epidemiological studies. Epidemiological studies are urgently needed to help uncover the burden of disease, in particular, the rate of asymptomatic infections, and to get better estimates on morbidity and mortality. Additionally, these epidemiological studies can help reveal the extent of virus spread in households, communities and specific settings; which could help guide control measures Serological assays are also needed for evaluation of the results of vaccine trials and development of therapeutic antibodies. Among the four coronavirus structural proteins, the spike (S) and the nucleocapsid (N) are the main immunogens (5) . Here, we describe development of serological assays for the detection of virus neutralizing antibodies and antibodies to the nucleocapsid (N) protein and various spike (S) domains including the S1 subunit, and receptor binding domain (RBD) of SARS-CoV-2 in ELISA format. Using a wellcharacterized cohort of serum samples from PCR-confirmed SARS-CoV-2 and patients PCR-confirmed to be infected with seasonal coronaviruses and other respiratory pathogens, we validated and tested various antigens in different platforms developed in-house as well as a commercial platform.

    Search related documents:
    Co phrase search for related documents
    • antigen test and binding domain: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
    • antigen test and control measure: 1, 2
    • antigen test and disease burden: 1, 2
    • antigen test and elisa format: 1
    • antigen test and epidemiological study: 1
    • antigen test and house develop: 1
    • asymptomatic infection and binding domain: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • asymptomatic infection and control measure: 1, 2
    • asymptomatic infection and disease burden: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21
    • asymptomatic infection and epidemiological study: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19
    • asymptomatic infection and house develop: 1, 2
    • asymptomatic infection rate and binding domain: 1, 2
    • asymptomatic infection rate and epidemiological study: 1
    • binding domain and coronavirus structural protein: 1, 2, 3, 4, 5, 6
    • binding domain and different platform: 1
    • binding domain and disease burden: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
    • binding domain and elisa format: 1, 2, 3, 4, 5, 6, 7, 8
    • binding domain and epidemiological study: 1, 2
    • binding domain and house develop: 1